DIG trial
Last reviewed 01/2018
The DIG trial investigated the role of cardiac glycosides in the treatment of patients with chronic heart failure and normal sinus rhythm.
Using a randomised, double-blind, placebo-controlled design, the trial measured the effect of digoxin on mortality and hospitalisation.
Patients with left ventricular ejection fractions of 0.45 or less were randomised to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors.
The median dose of digoxin was 0.25 mg per day. The mean follow-up was 37 months.
Reference:
- 1) The Digitalis Investigation Group. (1997) The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. N Engl J Med, 336, 525-33.